Alnis BioSciences, Inc.
|Primary Industry:||Pharma & Biotech|
|Executive Summary:||The convergence of diagnostic and therapeutic methods is leading to a new age of personalized medicine. Nowhere is this more important than in the treatment of cancer, a class of diseases characterized by uncontrolled growth of abnormal, genetically-mutated cells. Molecular diagnostic advances are providing valuable information on specific defects and potential targets found in tumor tissues, and the identification of cancer signatures that characterize an individual’s disease will continue to improve. This is important because current cell-killing treatments such as radiation and chemotherapy can not be sufficiently directed to tumors, and severe-side effects require treatment to be stopped before the patient is cured. Improved treatments are emerging- examples include monoclonal antibody therapies and nanoparticle delivery- and are based upon the targeting or exploitation of the distinguishing molecular and structural signatures of tumors. Alnis BioSciences is going beyond first generation targeting through the creation of MagNaGel™ nanoparticles that can be tracked in the body using MRI equipment already in place in hospitals to confirm tumor-localization, and that can then be selectively activated within tumors to eradicate cancer cells. MagNaGel nanoparticles combine diagnostic, drug and device capabilities to better detect, diagnose and treat cancer.|